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Abstract
Background
We have previously shown that fidaxomicin instillation prevents spore recovery in an in-vitro
gut model, whereas vancomycin does not. The reasons for this are unclear. Here, we have
investigated persistence of fidaxomicin and vancomycin on C. difficile spores, and exam-
ined post-antibiotic exposure spore recovery, outgrowth and toxin production.
Methods
Prevalent UK C. difficile ribotypes (n = 10) were incubated with 200mg/L fidaxomicin, van-
comycin or a non-antimicrobial containing control for 1 h in faecal filtrate or Phosphate Buff-
ered Saline. Spores were washed three times with faecal filtrate or phosphate buffered
saline, and residual spore-associated antimicrobial activity was determined by bioassay.
For three ribotypes (027, 078, 015), antimicrobial-exposed, faecal filtrate-washed spores
and controls were inoculated into broth. Viable vegetative and spore counts were enumer-
ated on CCEYL agar. Percentage phase bright spores, phase dark spores and vegetative
cells were enumerated by phase contrast microscopy at 0, 3, 6, 24 and 48 h post-inocula-
tion. Toxin levels (24 and 48h) were determined by cell cytotoxicity assay.
Results
Fidaxomicin, but not vancomycin persisted on spores of all ribotypes following washing in
saline (mean = 10.1mg/L; range = 4.0-14mg/L) and faecal filtrate (mean = 17.4mg/L; 8.4–
22.1mg/L). Outgrowth and proliferation rates of vancomycin-exposed spores were similar to
controls, whereas fidaxomicin-exposed spores showed no vegetative cell growth after 24
and 48 h. At 48h, toxin levels averaged 3.7 and 3.3 relative units (RU) in control and
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vancomycin-exposed samples, respectively, but were undetectable in fidaxomicin-exposed
samples.
Conclusion
Fidaxomicin persists on C. difficile spores, whereas vancomycin does not. This persistence
prevents subsequent growth and toxin production in vitro. This may have implications on
spore viability, thereby impacting CDI recurrence and transmission rates.
Introduction
Clostridium difficile infection (CDI) continues to be a leading infective cause of antibiotic-associ-
ated diarrhoea, placing substantial burdens on healthcare systems worldwide.[1, 2] Morbidity
and mortality, particularly associated with recurrent disease, remain problematic, with ~25% of
patients experiencing a recurrence of symptoms following treatment.[3, 4] A key contributing
factor to the high rates of recurrence associated with CDI is the persistence of C. difficile spores in
the intestinal lumen (or mucosal associated biofilm) following treatment.[5] These are unaffected
by standard antimicrobial therapy, and provide a key reservoir for recurrent disease, allowing re-
establishment of a vegetative C. difficile population following successful initial treatment.[6, 7]
For many years, treatment options were limited to vancomycin and metronidazole. How-
ever, the recent introduction of fidaxomicin offers a therapeutic alternative. In phase III clinical
trials fidaxomicin was non inferior to vancomycin for initial clinical cure, but was superior in
preventing recurrence and sustained clinical sure.[8–10]
We have previously observed that fidaxomicin activity continues to be detected for pro-
longed periods of time in an in vitro gut model,[7, 11] whereas vancomycin activity quickly
washes out.[12] Similar prolonged detection of antimicrobial activity has been observed for
both ramoplanin [13] and oritavancin,[14] and has correlated with an association of antimicro-
bial activity on C. difficile spores, which persists despite washing.[15, 16] We have termed this
‘persistence of activity’. In this study, we have quantified the persistence of fidaxomicin activity
on C. difficile spores, and demonstrate that this persistence affects spore recovery, spore out-
growth, vegetative cell growth and toxin production.
Methods
Ethics statement
The collection/use of faecal donations from healthy adult volunteers was approved by the
Leeds Institute of Health Sciences and Leeds Institute of Genetics, Health and Therapeutics
and Leeds Institute of Molecular Medicine, University of Leeds joint ethics committee (refer-
ence HSLTLM/12/061). Written consent was not obtained from participants in order to main-
tain anonymity, and reduce any embarrassment on the part of the participant. The
participation leaflet explained that by providing a sample and giving it to the research team,
informed consent for use of the sample in this study was implicit. This consent process was
approved by the ethics committee.
C. difficile strains
Ten different C. difficile strains comprising the most common PCR ribotypes in the UK in
2013 (RT015, RT020, RT078, RT023, RT005, RT026, RT027, RT001, RT002, RT014) were
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selected from those submitted to the Clostridium difficile Ribotyping Network (CDRN) during
this year. All strains were toxigenic clinical isolates from the UK. Three strains were selected
for further studies. RT027 was chosen as an example of this highly epidemic ribotype. RT078
was chosen because strains of this ribotype have also been associated with clinical outbreaks,
and are genetically distinct from other ribotypes. RT005 was chosen as an example of a non-
epidemic ribotype.
Preparation of C. difficile spores
Each strain was reconstituted on Brazier’s Cefoxitin, Cycloserine, Egg Yolk, Lysoyme (CCEYL)
agar (final lysozyme concentration 5mg/L). Strains were checked for purity, before single pas-
sage on CCEYL agar. After 48 h, growth from each plate was harvested on a sterile swap, and
transferred to pre-reduced Colombia Blood Agar (CBA) plates. Plates were incubated anaero-
bically at 37°C for 14 days, and then all growth was harvested into 50% EtOH in PBS. Spore
preps were enumerated on CCEYL agar and visually checked for purity by phase contrast
microscopy. Spore preparations were standardised to ~107 cfu/mL.
Enumeration of C. difficile spores
Samples were subject to a 10-fold serial dilution series (to 10−7) in peptone water. Twenty
microliters of each dilution was plated onto Brazier’s CCEYL agar in triplicate and incubated at
37°C. CCEYL agar containing lysozyme was used in order to stimulate germinating spores
(unrelated to classical germination pathways) to ensure maximum recovery/enumeration. Col-
onies were counted from a dilution with ~20–100 colonies to calculate cfu/mL. The limit of
detection was 1.22 log10 cfu/mL.
Preparation of faecal filtrate
Faecal samples from 3 healthy, adult volunteers (transported and stored anaerobically) were
pooled, mixed with pre-reduced PBS (10%w/v), mixed with a stomacher and passed through a
course muslin filter to remove large particulate matter. Aliquots of the resultant slurry were
centrifuged (15 mins, 10,000g) and the supernatant sterilised by filtration through 22μm filters.
This 10% faecal filtrate (FF) was stored at 4°C for a maximum of 1 week.
Antibiotic exposure and washing procedure
For each of the ten clinical isolates, replicate spore preps (n = 9) were exposed to 200mg/L
fidaxomicin, 200mg/L vancomycin or a non-antimicrobial-containing control in either PBS or
FF for 1 hour. Aliquots (1mL) were washed in PBS or FF. During washing, samples were centri-
fuged (5 minutes,>16,000g), all excess supernatant removed by pipette, and pellets resus-
pended in wash solution by pipetting. Each aliquot was washed five times, with the sample
moved to a fresh Eppendorf tube between washes 3 and 4 to prevent carry over of residual anti-
biotic. Following washing, spores were frozen at -20°C until subsequent use.
Determination of active antimicrobial concentration by bioassay
Bioassay agar (100mL) was sterilised by autoclave, cooled to 50°C, seeded with 1mL indicator
organism (0.5 MacFarlane standard suspension in PBS) and pored into 245 mm x 245 mm bio-
assay dishes. Once set, plates were dried, and 25x 9 mm wells dug in the agar (no. 5 cork
borer). Washed spore samples (20 μL) were inoculated into wells alongside a doubling dilution
calibration series of known antibiotic concentration. After 24 h growth at 37°C, zones of inhibi-
tion were measured using callipers accurate to 0.1mm. Calibration lines were plotted from
Fidaxomicin Persistence on C. difficile Spores
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squared zone diameters, and active antimicrobial concentration was calculated from the cali-
bration lines. All samples were assayed in triplicate against a calibration curve of both fidaxo-
micin and vancomycin. The fidaxomicin bioassay was performed onWilkins-Charlgren agar
with Kocuria rhizophila (ATCC 9341) indicator organism, and a calibration series ranging
from 2–128 mg/L (limit of detection ~0.5mg/L). The vancomycin bioassay was performed on
Muller Hinton Agar with Staphylococcus aureus (ATCC 29 213) indicator organism and a
2–128 mg/L calibration series (limit of detection ~1mg/L). Limits of detection refer to the low-
est concentration that creates a measurable zone of inhibition. The residual activity of samples
following washing was determined using the calibration curve of the relevant exposure
antimicrobial.
Recovery of antibiotic-exposed, washed spores
Following antibiotic exposure and washing in FF, spore aliquots were diluted in a 10-fold series
in peptone water to 10−7 and enumerated as described above.
Outgrowth and toxin production following germination of antibiotic-
exposed, washed spores
For the three strains investigated in more detail (RT027, RT078, RT005), antibiotic-exposed,
FF washed spores were inoculated into pre-reduced Brain Heart Infusion broth (BHI) along-
side a non antibiotic-exposed, FF washed control. Samples were taken at 0, 3, 6, 24 and 48
hours post inoculation (triplicate biological and technical replicates for each strain, n = 9).
Total viable counts were enumerated on CCEYL agar (as described above) following dilution
(10-fold series) in peptone water. Following alcohol shock (50% EtOH for 1 hour), samples
were again diluted and inoculated on CCEYL agar to enumerate spores. At each time point,
samples (20 μL) were dried on glass microscope slides, and overlaid with Wilkins-Charlgren
agar (50 μL) and a glass cover slip for phase microscopy. One hundred entities were recorded
from at least three different fields of view, and % phase bright (dormant) spores, phase dark
(germinating) spores and vegetative cells calculated. At 6, 24 and 48 h, toxin was enumerated
using a cell cytotoxicity assay. Briefly, samples were diluted 10-fold in PBS and applied to a
Vero cell monolayer. At 24 and 48 hours, toxin mediated cell rounding was assessed against
control wells. Rounding in>80% of cells was considered positive. A sample positive for toxin
in the neat well only was assigned a toxin titre of 1 relative unit. A sample positive for toxin in
the neat and 10−1 wells was assigned a toxin titre of 2 and so on. Clostridium sordellii antitoxin
was used to confirm specificity.
Statistical analysis
Statistical significance of differences in viable counts was determined using the two-sample t-
test carried out with StataIC 13 software package. P values<0.005 were consisted significant.
Results
Fidaxomicin-exposed spore samples retained detectable antimicrobial activity following wash-
ing in PBS, whereas vancomycin-exposed and non-antibiotic-exposed control spore samples
did not (Fig 1A). The retention of activity varied between strains and ranged from ~4.0 mg/L
(RT015) to ~14.5 mg/L (RT002). The same phenomenon was observed following washing in
the more in vivo reflective faecal filtrate (FF), with antimicrobial activity again detected in
fidaxomicin-exposed, but not vancomycin-exposed or control spores (Fig 1B). Interestingly,
washing in FF following fidaxomicin exposure caused significantly greater antimicrobial
Fidaxomicin Persistence on C. difficile Spores
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Fig 1. Mean (±SE, n = 9) active antimicrobial concentration post-washing in (a) PBS and (b) FF for spores of 10 different ribotypes.
Horizontal dashed line indicated limit of bioassay detection. Statistical significance was determined using two-sample t-test.
doi:10.1371/journal.pone.0161200.g001
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activity to be retained on spore aliquots compared with PBS (Fig 2). Again this varied accord-
ing to strain, although the difference was significant (p0.005) for all strains. In some cases
(RT015, RT026, RT001, RT002), approximately twice the detectable activity was retained fol-
lowing washing in FF compared with PBS (Fig 2).
Retention of antimicrobial activity prevented recovery of spores on CCEYL agar. No growth
was recovered from fidaxomicin-exposed washed spore preps, but recovery from vancomycin-
exposed washed spore preps was not significantly different to recovery from control samples
(p = 0.21) at ~8 log10 cfu/mL (Fig 3). However, this prevention of recovery was lost following
dilution of the washed spores. At lower concentrations (100-fold dilution), there was no sig-
nificant difference in the recovery of fidaxomicin-exposed, washed spore preps compared with
control samples (p = 0.14) (Fig 3).
Retention of antimicrobial activity also affected downstream vegetative growth and toxin
production of fidaxomicin-exposed washed spores in BHI broth culture, although the early ger-
mination events (transformation of phase bright spores to phase dark) were unaffected. In all
samples, phase microscopy demonstrated a decrease in percentage phase bright spores and cor-
responding increase in phase dark spores over the first 3–6 hours as spores germinated (Figs 4–
6, panels 2). For each of the three strains assayed (RT027, RT078 and RT005), control (non
antibiotic-exposed) washed spores showed an increase in total viable counts compared with
spore counts at 24 and 48 h (Figs 4–6). For RT027, this increase was also evident at 6 h (Fig 5).
Fig 2. Mean (±SE, n = 9) active fidaxomicin concentration post-washing in PBS or faecal filtrate (FF) for spores of 10 different ribotypes. Statistical
significance was determined using two-sample t-test.
doi:10.1371/journal.pone.0161200.g002
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Corresponding phase microscopy confirmed that by 24 hours, the proportion of vegetative
cells had increased markedly relative to spores. Vancomycin-exposed washed spores germi-
nated, outgrew and proliferated in the same manner as control samples (Figs 4–6).
No significant differences were observed in the total viable counts of the control and vanco-
mycin-exposed samples at 24 (p = 0.02) or 48 hours (p = 0.11). However, for fidaxomicin-
exposed samples, significantly lower total viable counts were observed compared with controls
at both 24 and 48 hours (p<0.001). This was confirmed by phase microscopy, where fidaxomi-
cin-exposed spores germinated (decrease in % phase bright spores, increase in % phase dark
spores), but did not undergo outgrowth into vegetative cells (%vegetative cells remained lower
than control samples, even after 24 h). Importantly, toxin was detected in control and vanco-
mycin-exposed samples after 24 and 48 h, whereas no toxin was identified in fidaxomicin-
exposed samples (Figs 4–6).
Discussion
We have demonstrated that detectable fidaxomicin activity continues to be associated with C.
difficile spores following washing, preventing subsequent spore recovery, whereas vancomycin
Fig 3. Mean (±SE, n = 30)C. difficile counts (log10 cfu/mL) for all strains following inoculation of faecal filtrate (FF) washed spores onto
CCEYL agar. Statistical significance was determined using two-sample t-test. Horizontal dashed line indicates limit of detection (1.22 log10 cfu/
mL). #a = Too many colonies to count at neat dilution, therefore log10 cfu/mL extrapolated from a countable dilution. #b = no growth at neat
dilution, log10 cfu/mL recorded as limit of detection. #c = log10 cfu/mL in 10
−4 dilution.
doi:10.1371/journal.pone.0161200.g003
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activity does not. Furthermore, in the three clinical isolates tested here, this persistence of activ-
ity prevented vegetative outgrowth and toxin production in batch culture.
It has been widely reported that different C. difficile strains exhibit variable growth dynam-
ics, sporulation and germination rates and toxin production [17–19]. We have therefore used
10 clinical isolates, belonging to different PCR ribotypes, to evaluate any strain-to-strain varia-
tion in the persistence of fidaxomicin activity. This approach helps to strengthen our observa-
tions, and ensures observed effects are not strain-specific anomalies. While the extent of
fidaxomicin persistence varied between the 10 strains tested here, a detectable active concentra-
tion of>4 mg/L was observed in all cases, which is substantially higher than the MIC of fidaxo-
micin against these 10 strains tested (MIC range = 0.03–0.06 mg/L), and C. difficile isolates
recently reported across Europe (range 0.002–0.25)[20]. It has previously been reported that
exposure to both fidaxomicin and vancomycin [21] and also oritavancin [15] inhibits out-
growth of C. difficile spores, whilst not preventing the early germination events that manifest in
the transformation of phase bright spores to phase dark. Therefore, it would be expected that at
these supra-MIC levels, persisting fidaxomicin activity would act on germinating spores,
Fig 4. Growth of Control (non-antibiotic exposed washed spores), Vanc-exposed (vancomycin-exposed washed spores) and Fdx-exposed
(Fidaxomicin-exposed washed spores) of strain RT078 following inoculation into BHI broth. Panel 1: Mean (n = 9) total viable counts (TVC, log10 cfu/
mL), spore counts (Spore, log10 cfu/mL) and toxin titre (relative units) at tome points 0, 3, 6, 24 and 48 hours. Panel 2: Corresponding mean percentage
vegetative cells (Av %V), phase dark spores (Av %PD), and phase bright spores (Av %PB) at time points 0, 3, 6 and 24 hours.
doi:10.1371/journal.pone.0161200.g004
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preventing outgrowth (and hence recovery on agar). This is confirmed by the data presented
here showing that fidaxomicin-exposed spores could not be recovered on CCEYL agar, whereas
control and vancomycin-exposed spores were recovered.
Following inoculation into BHI, non-antimicrobial exposed control spores and vancomycin
exposed spores germinated, and outgrew into a proliferating vegetative population, despite no
additional supplementation with classical germinants. Other authors have also reported germi-
nation of clinical isolates in the absence of additional supplementation with classical germi-
nants [17]. BHI was used as a toxin production promoting media to assess downstream affects
on toxin levels. Fidaxomicin-exposed spores inoculated into BHI undergo early germination
events (as shown by transformation of spores from phase bright to phase dark), but no out-
growth to vegetative cells occurred. This is in agreement with previously published work. [21]
Crucially from a clinical standpoint, this lack of vegetative cell growth led to a lack of detectable
toxin–the key disease determinant in CDI.
The mechanism for fidaxomicin association with spores remains unknown, but the antibi-
otic has also been shown to adhere to glassware. [22] It is likely that fidaxomicin adheres to the
Fig 5. Growth of Control (non-antibiotic exposed washed spores), Vanc-exposed (vancomycin-exposed washed spores) and Fdx-exposed
(Fidaxomicin-exposed washed spores) of strain RT027 following inoculation into BHI broth. Panel 1: Mean (n = 9) total viable counts (TVC, log10 cfu/
mL), spore counts (Spore, log10 cfu/mL) and toxin titre (relative units) at tome points 0, 3, 6, 24 and 48 hours. Panel 2: Corresponding mean percentage
vegetative cells (Av %V), phase dark spores (Av %PD), and phase bright spores (Av %PB) at time points 0, 3, 6 and 24 hours.
doi:10.1371/journal.pone.0161200.g005
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exosporium of C. difficile (as has recently been shown for ramoplanin[16]), potentially due to
electrostatic charges resulting form cross-linkages on the spore surfaces. The presence of the
exosporium has been shown to increase hydrophobicity of C. difficile spores, and affect adher-
ence to cells[23]. Fidaxomicin is a hydrophobic molecule, and it is therefore probable that
spore hydrophobicity is an important factor in its adherence; strain-to-strain differences in
spore exosporium and hydrophobicity may contribute to the observed variation in levels of
fidaxomicin persistence. It would be desirable to directly visualise the binding of fidaxomicin
to spores; however, conjugation of fluorescent markers to fidaxomicin is problematic due to
the lack of amenable functional groups. Future experiments aim to explore alternative tech-
niques for imaging of fidaxomicin such as Imaging Mass Spectrometry.
Kraus et al [16] demonstrated that ramoplanin binds to the exosporium of C. difficile, pre-
venting recovery on agar plates. Interestingly, they also reported that this effect can be diluted
out, and postulate that a concentration equilibrium is achieved between the exosporium and
the supernatant over time; dilution lowers the local antimicrobial concentration to below the
MIC, thereby allowing spore outgrowth. Our data suggest that the same dilution effect occurs
Fig 6. Growth of Control (non-antibiotic exposed washed spores), Vanc-exposed (vancomycin-exposed washed spores) and Fdx-exposed
(Fidaxomicin-exposed washed spores) of strain RT005 following inoculation into BHI broth. Panel 1: Mean (n = 9) total viable counts (TVC, log10 cfu/
mL), spore counts (Spore, log10 cfu/mL) and toxin titre (relative units) at tome points 0, 3, 6, 24 and 48 hours. Panel 2: Corresponding mean percentage
vegetative cells (Av %V), phase dark spores (Av %PD), and phase bright spores (Av %PB) at time points 0, 3, 6 and 24 hours.
doi:10.1371/journal.pone.0161200.g006
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with fidaxomicin, and once the local concentration on the plate falls below the MIC (1:100
dilution required for fidaxomicin-exposed spores to grow, whereas 1:10 dilution allowed
growth of ramoplanin-exposed spores [16]), spore recovery returns to normal. This hypothesis
would also explain the results following inoculation into BHI. If a concentration equilibrium is
achieved between the spores and supernatant, this would be likely to be a supra-MIC concen-
tration (thereby preventing spore outgrowth and vegetative proliferation, hence preventing
toxin production). However, the dilution process associated with enumeration then lowers the
concentration enough to allow recovery on CCEYL.
Persisting fidaxomicin activity can be removed by washing spores in ethanol or DMSO [24],
which is likely to be due to the high solubility of fidaxomicin in these solvents. However, inves-
tigating persistence of activity following washing of spores in PBS, ethanol or DMSO bears little
resemblance to conditions in the colon, and is likely to have little significance in elucidating the
importance of this phenomenon clinically. We have therefore investigated the persistence of
activity following washing in faecal filtrate. Whilst this is still not fully representative of the
complex, multispecies environment of the colon, it is far more clinically reflective than other
washing agents. Interestingly, when spores were washed in faecal filtrate, the level of detectable
fidaxomicin activity was greater than following washing in PBS. The reasons for this are
unclear, but are likely to relate to the biophysical properties of faeces, e.g. salt concentrations
affecting solubility. Taken with the fact that persistence of activity following fidaxomicin treat-
ment and a lack of spore recovery have both been reported in a clinically reflective human gut
model,[7] this suggests that this persistence of activity on spores is likely to occur in vivo.
The persistence of fidaxomicin activity on spores may confer an advantage over other CDI
treatment agents such as vancomycin. The data presented here show that in batch culture this
persistence prevents downstream outgrowth of spores into vegetative cells, and crucially subse-
quent toxin production, suggesting that this is likely to be important factor in the observed
reduced rates of recurrence following fidaxomicin treatment. Recurrence is a major issue in
CDI treatment, with ~25% of patients experiencing a re-occurrence of symptoms following
treatment. Recurrence can be due to a recrudescence of spores remaining in the gut following
an infection, or a re-infection of a still-susceptible patient with a ‘new’ infective dose of C. diffi-
cile.[3] Comparative trials have reported that fidaxomicin is superior to vancomycin in preven-
tion of recurrences, particularly in the first two weeks after antibiotic cessation.[8] We have
previously postulated that this may be due to a persistence of fidaxomicin in the gut as
observed in an in vitro gut model [7] and in patients during Phase I human volunteer studies.
[25] However, specific persistence on any residual spores remaining in a patient’s gut following
fidaxomicin treatment may have additional benefits. This would localise the persisting activity
to the germinating spore, where it can act early to prevent outgrowth, therefore preventing
recrudescence of vegetative cell proliferation and toxin production. To this end, dosing strate-
gies that maximise persistence of fidaxomcin activity in the gut are being investigated. [11, 26]
If detectable activity can persist on spores ‘shed’ by fidaxomicin treated patients, this may have
important infection control benefits in helping to prevent cell growth following spore transmis-
sion. The level of persistence on spores in the environment, and the clinical effects of this per-
sistence should be investigated further. It would also be of interest to investigate the longevity
of persisting fidaxomicin activity on C. difficile spores, and whether this persistence affects the
ability of spores to initiate an infection in an in vitro gut model, or when transferred orally in a
rodent model of CDI.
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